公开(公告)号：US20040171647A1

公开(公告)日：2004-09-02

申请号：US10796354

申请日：2004-03-08

Applicant: Sepracor Inc.

Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439 ,  A61K31/00

Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

公开(公告)号：US20020052382A1

公开(公告)日：2002-05-02

申请号：US09988935

申请日：2001-11-19

Applicant: Sepracor Inc.

Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/496

CPC classification number: A61K31/496 ,  C07D249/12

Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.

Abstract translation: 奈法唑酮的羟基代谢物的R-异构体R-羟基吗啡酮是抑制剂的有效治疗剂，其不会引起与奈法唑酮相关的不良反应。 R-羟基吗唑酮也可用于治疗偏头痛，恐慌症，创伤后应激障碍和睡眠障碍。

公开(公告)号：US20020115691A1

公开(公告)日：2002-08-22

申请号：US10082571

申请日：2002-02-25

Applicant: SEPRACOR INC.

Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439 ,  A61K31/00

Abstract: Methods and compositions are disclosed utilizing optically pure (null) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯（ - ）雷贝拉唑治疗人类溃疡的方法和组合物，同时显着降低与雷贝拉唑外消旋混合物相关的副作用的伴随的责任。 光学纯的（ - ）异构体也可用于治疗胃食管反流。 （ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

公开(公告)号：US20020099079A1

公开(公告)日：2002-07-25

申请号：US10046464

申请日：2001-10-19

Applicant: SEPRACOR INC.

Inventor： William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439

Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了利用羟基索非唑来治疗人类溃疡的方法和组合物。 羟考兰唑与兰索拉唑相比显着降低药物相互作用的责任，比兰索拉唑更可预测的给药方案。 羟基索非唑还可用于治疗胃食管反流和其他与胃分泌过多相关的病症，例如Zollinger-Ellison综合征。

公开(公告)号：US20040266792A1

公开(公告)日：2004-12-30

申请号：US10891236

申请日：2004-07-13

Applicant: Sepracor Inc.

Inventor： William E. Yelle

IPC: A61K031/519 ,  A61K031/675

CPC classification number: A61K31/505 ,  A61K31/51 ,  A61K31/675

Abstract: Methods and compositions utilizing compounds represented by Formula III, 1 or a pharmaceutically acceptable salt thereof, for the treatment and prevention of psychoses in humans are disclosed. Compounds of the present invention exhibit fewer side effects than risperidone, a lessened liability toward drug-drug interactions than risperidone and a more predictable dosing regimen than risperidone. Compounds of the invention are also useful for the treatment and prevention of emesis and withdrawal syndromes.

公开(公告)号：US20040077688A1

公开(公告)日：2004-04-22

申请号：US10685628

申请日：2003-10-14

Applicant: SEPRACOR INC.

Inventor： William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439

Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了利用羟基索非唑来治疗人类溃疡的方法和组合物。 羟考兰唑与兰索拉唑相比显着降低药物相互作用的责任，比兰索拉唑更可预测的给药方案。 羟基索非唑还可用于治疗胃食管反流和其他与胃分泌过多相关的病症，例如Zollinger-Ellison综合征。

公开(公告)号：US20030008903A1

公开(公告)日：2003-01-09

申请号：US10216962

申请日：2002-08-12

Applicant: Sepracor Inc.

Inventor： Timothy J. Barberich ,  William E. Yelle ,  Paul D. Rubin

IPC: A61K031/4439

CPC classification number: A61K31/4439

Abstract: Methods and compositions are disclosed utilizing optically pure (null) lansoprazole for the treatment of S ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Lansoprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 使用光学纯的（+）兰索拉唑用于治疗人类S溃疡的方法和组合物，同时显着减少与兰索拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）兰索拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

公开(公告)号：US20020082251A1

公开(公告)日：2002-06-27

申请号：US10026303

申请日：2001-12-19

Applicant: SEPRACOR INC.

Inventor： William E. Yelle

IPC: A61K031/55

CPC classification number: A61K31/551

Abstract: Methods and compositions are disclosed utilizing N-desmethylolanzapine for the treatment of psychosis in humans. N-Desmethylolanzapine exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. N-Desmethylolanzapine is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.

Abstract translation: 公开了使用N-去甲基氯氮平治疗人类精神病的方法和组合物。 N-甲基羟基兰氮平显示与奥氮平相比，药物相互作用的责任减少，而奥氮平更可预测给药方案。 N-去甲基氯氮平还可用于治疗急性躁狂症，轻度焦虑症，焦虑症，精神分裂症，双相情感障碍，注意缺陷多动障碍，自闭症，过度侵略，药物滥用，抑郁症状和症状，抽搐障碍，功能性肠病 和真菌性皮炎。

公开(公告)号：US20020065272A1

公开(公告)日：2002-05-30

申请号：US10016205

申请日：2001-10-30

Applicant: SEPRACOR INC.

Inventor： William E. Yelle

IPC: A61K031/5513

CPC classification number: A61K31/5513 ,  A61K31/551 ,  Y10S514/81 ,  Y10S514/811 ,  Y10S514/812

Abstract: Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. Olanzapine-N-oxide is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.

公开(公告)号：US20030069280A1

公开(公告)日：2003-04-10

申请号：US10263558

申请日：2002-10-02

Applicant: SEPRACOR INC.

Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439 ,  A61K31/00

Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。